Organogenesis Holdings Inc (ORGO) Stock Price, Quote & News

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 575 0775

Website: organogenesis.com

Address:

85 Dan Road, Canton, United States

resistancebreakers Jun. 4 at 1:59 PM

$ORGO 29% short interest

0 · Reply

Mobagri Jun. 2 at 1:43 PM

$ORGO why is it dropping ?

1 · Reply

resistancebreakers Jun. 2 at 9:11 AM

$ORGO ready 🪖🫡☝️

0 · Reply

resistancebreakers May. 29 at 9:08 AM

$ORGO looks ready

1 · Reply

DARKP00L May. 28 at 12:39 PM

$ORGO 07:52 on May. 28 2026 Truist Securities Initiates Coverage On Organogenesis Holdings with Hold Rating, Announces Price Target of $3 #tradeideas

0 · Reply

Monticello4 May. 27 at 10:26 PM

$ORGO . Short Interest most recent released data (today): MiMedx short interest dropped 1,087,706 shares ORGO short interest INCREASED by 371,775 shares

0 · Reply

josegodoy May. 27 at 3:41 PM

$ORGO ⏳

1 · Reply

jcooptechit May. 26 at 4:30 PM

$CNXU JUST HIT NASDAQ | REGENERATIVE MEDICINE WATCHLIST ALERT Conexeu Sciences is now trading on Nasdaq under CNXU, advancing its proprietary CXU tissue regeneration platform. Here's The Alpha: 🔹 Nasdaq listing milestone 🔹 Patented CXU ECM platform 🔹 B.R.E.A.S.T. 3D-bioprinted regenerative breast matrix 🔹 Ten Minute Tissue injectable ECM Targeting wound care, aesthetics, GLP-1 tissue loss, periodontal care, biofabrication & vet markets CNXU is positioning around a big idea: helping the body restore lost or damaged tissue, not just replace it. This is one to watch early. ⚡️ Communicated - Disclaimer: https://stockresearchtoday.com/cnxu/ Sector Peers: $ORGO $MDXG $MDWD $HUMA

0 · Reply

josegodoy May. 22 at 7:07 PM

$ORGO Analyst: Ryan Zimmerman - approx success 40% rate BTIG: - has been wrong on ORGO for a very long time - they seem to be all over the place (on ORGO PTs) every couple of months as well “BTIG adjusted its price target for Organogenesis Holdings (NASDAQ:ORGO) to $8 on MARCH 26, 2026. Prior to that, they had the stock rated at a $9 target (NOVEMBER 2025 (see link below)). Please note that shortly after on MAY 8, 2026, BTIG downgraded Organogenesis to Neutral and completely withdrew their price target due to…” NOVEMBER 2025: PT from $7>>$9 https://m.investing.com/news/analyst-ratings/organogenesis-stock-price-target-raised-to-9-by-btig-on-reimbursement-changes-93CH-4370129?ampMode=1

0 · Reply

Monticello4 May. 22 at 3:52 PM

$ORGO

0 · Reply

Organogenesis initiated with a Hold at Truist

2026-05-08T11:17:55.000Z - 27 days ago

Organogenesis downgraded to Neutral from Buy at BTIG

May 7, 2026, 5:00 PM EDT - 4 weeks ago

Organogenesis Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 4 weeks ago

Organogenesis Holdings Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 4 weeks ago

Organogenesis Holdings Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 4 weeks ago

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Organogenesis Holdings Proxy statement: Proxy filing

2026-04-28T22:00:57.000Z - 5 weeks ago

Organogenesis completes rolling submission of ReNu BLA

Apr 28, 2026, 4:30 PM EDT - 5 weeks ago

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

2026-04-07T12:03:59.000Z - 2 months ago

Why is Organogenesis Stock (ORGO) Up 20% Today?

2026-04-06T23:05:09.000Z - 2 months ago

Organogenesis achieves primary endpoint in PuraPly study

Apr 6, 2026, 7:02 PM EDT - 2 months ago

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

2026-04-06T21:35:17.000Z - 2 months ago

Organogenesis announces successful FDA meeting, plans to file BLA for ReNu

Apr 6, 2026, 5:30 PM EDT - 2 months ago

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Apr 6, 2026, 7:30 AM EDT - 2 months ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

2026-02-27T12:39:51.000Z - 3 months ago

Organogenesis price target lowered to $8 from $9 at BTIG

Feb 26, 2026, 5:00 PM EST - 3 months ago

Organogenesis Holdings Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Organogenesis Holdings Earnings release: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Organogenesis Holdings Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Organogenesis Holdings Annual report: Q4 2025

Feb 26, 2026, 4:05 PM EST - 3 months ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

Feb 19, 2026, 4:05 PM EST - 3 months ago

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

2025-12-23T21:10:37.000Z - 5 months ago

Organogenesis initiates rolling submission of BLA to FDA for ReNu

Dec 23, 2025, 4:05 PM EST - 5 months ago

Organogenesis Announces Initiation of Biologics License Application for ReNu®

2025-12-15T21:30:39.000Z - 6 months ago

Organogenesis plans to file BLA for ReNu before end of December

2025-11-20T12:16:47.000Z - 7 months ago

Organogenesis price target raised to $9 from $7 at BTIG

Nov 6, 2025, 5:00 PM EST - 7 months ago

Organogenesis Holdings Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Organogenesis Holdings Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Organogenesis Holdings Earnings release: Q3 2025

Nov 6, 2025, 4:05 PM EST - 7 months ago

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

Nov 3, 2025, 1:10 PM EST - 7 months ago

Organogenesis Applauds CMS's Significant Step In Payment Reform

Oct 31, 2025, 4:05 PM EDT - 7 months ago

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 17, 2025, 2:20 PM EDT - 8 months ago

Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO

Oct 1, 2025, 4:05 PM EDT - 8 months ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

2025-09-25T20:55:11.000Z - 9 months ago

Organogenesis provides update on second Phase 3 ReNu study

Sep 25, 2025, 4:50 PM EDT - 9 months ago

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Sep 3, 2025, 2:10 PM EDT - 9 months ago

Organogenesis Holdings Transcript: Cantor Global Healthcare Conference 2025

Aug 27, 2025, 4:05 PM EDT - 10 months ago

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Organogenesis Holdings Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Organogenesis Holdings Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Organogenesis Holdings Earnings release: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 10 months ago

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:05 PM EDT - 11 months ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

Jul 15, 2025, 9:00 AM EDT - 11 months ago

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

May 12, 2025, 8:00 AM EDT - 1 year ago

Organogenesis Holdings Proxy statement: Proxy Filing

May 8, 2025, 5:00 PM EDT - 1 year ago

Organogenesis Holdings Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Organogenesis Holdings Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Organogenesis Holdings Earnings release: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Organogenesis Holdings Proxy statement: Proxy Filing

Apr 11, 2025, 4:05 PM EDT - 1 year ago

Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Feb 27, 2025, 5:00 PM EST - 1 year ago

Organogenesis Holdings Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Organogenesis Holdings Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Organogenesis Holdings Earnings release: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Jan 27, 2025, 7:30 AM EST - 1 year ago

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

Dec 19, 2024, 7:00 AM EST - 1 year ago

Organogenesis Holdings Registration statement: Registration Filing

Nov 22, 2024, 4:05 PM EST - 1 year ago

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Nov 15, 2024, 9:25 AM EST - 1 year ago

Organogenesis Commends Final LCDs

Nov 12, 2024, 5:00 PM EST - 1 year ago

Organogenesis Holdings Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Organogenesis Holdings Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Organogenesis Holdings Earnings release: Q3 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Nov 11, 2024, 5:05 PM EST - 1 year ago

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

Oct 1, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

Sep 18, 2024, 1:20 PM EDT - 1 year ago

Organogenesis Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 8, 2024, 5:00 PM EDT - 1 year ago

Organogenesis Holdings Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 1 year ago

Organogenesis Holdings Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 1 year ago

Organogenesis Holdings Earnings release: Q2 2024

Aug 8, 2024, 4:04 PM EDT - 1 year ago

Organogenesis Shares ReNu® Program Update

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Organogenesis Holdings Registration statement: Registration Filing

Jul 15, 2024, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Jun 6, 2024, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

May 9, 2024, 5:00 PM EDT - 2 years ago

Organogenesis Holdings Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Organogenesis Holdings Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Organogenesis Holdings Earnings release: Q1 2024

May 2, 2024, 7:00 AM EDT - 2 years ago

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Organogenesis Holdings Proxy statement: Proxy Filing

Apr 16, 2024, 7:30 AM EDT - 2 years ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Feb 29, 2024, 5:00 PM EST - 2 years ago

Organogenesis Holdings Earnings Call Transcript: Q4 2023

Feb 29, 2024, 5:00 PM EST - 2 years ago

Organogenesis Holdings Annual report: Q4 2023

Feb 29, 2024, 5:00 PM EST - 2 years ago

Organogenesis Holdings Earnings release: Q4 2023

Feb 29, 2024, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Feb 12, 2024, 7:30 AM EST - 2 years ago

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Feb 8, 2024, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Nov 9, 2023, 5:00 PM EST - 2 years ago

Organogenesis Holdings Earnings Call Transcript: Q3 2023

Nov 9, 2023, 5:00 PM EST - 2 years ago

Organogenesis Holdings Quarterly report: Q3 2023

Nov 9, 2023, 5:00 PM EST - 2 years ago

Organogenesis Holdings Earnings release: Q3 2023

Nov 9, 2023, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

Oct 5, 2023, 7:30 AM EDT - 2 years ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

Sep 28, 2023, 9:15 AM EDT - 2 years ago

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Organogenesis Holdings Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 6, 2023, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 9, 2023, 5:00 PM EDT - 3 years ago

Organogenesis Holdings Earnings Call Transcript: Q2 2023

Aug 9, 2023, 5:00 PM EDT - 3 years ago

Organogenesis Holdings Quarterly report: Q2 2023

Aug 9, 2023, 5:00 PM EDT - 3 years ago

Organogenesis Holdings Earnings release: Q2 2023

Aug 9, 2023, 4:05 PM EDT - 3 years ago

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

Jul 10, 2023, 7:30 AM EDT - 3 years ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

May 21, 2023, 8:20 AM EDT - 3 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CABA CYH EXAS MRNA NVAX PFE RARE

May 10, 2023, 5:00 PM EDT - 3 years ago

Organogenesis Holdings Earnings Call Transcript: Q1 2023

May 10, 2023, 5:00 PM EDT - 3 years ago

Organogenesis Holdings Quarterly report: Q1 2023

May 10, 2023, 5:00 PM EDT - 3 years ago

Organogenesis Holdings Earnings release: Q1 2023

May 10, 2023, 4:05 PM EDT - 3 years ago

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

May 1, 2023, 8:00 AM EDT - 3 years ago

Organogenesis Holdings Proxy statement: Proxy Filing

Apr 27, 2023, 7:30 AM EDT - 3 years ago

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

resistancebreakers Jun. 4 at 1:59 PM

$ORGO 29% short interest

0 · Reply

Mobagri Jun. 2 at 1:43 PM

$ORGO why is it dropping ?

1 · Reply

resistancebreakers Jun. 2 at 9:11 AM

$ORGO ready 🪖🫡☝️

0 · Reply

resistancebreakers May. 29 at 9:08 AM

$ORGO looks ready

1 · Reply

DARKP00L May. 28 at 12:39 PM

$ORGO 07:52 on May. 28 2026 Truist Securities Initiates Coverage On Organogenesis Holdings with Hold Rating, Announces Price Target of $3 #tradeideas

0 · Reply

Monticello4 May. 27 at 10:26 PM

$ORGO . Short Interest most recent released data (today): MiMedx short interest dropped 1,087,706 shares ORGO short interest INCREASED by 371,775 shares

0 · Reply

josegodoy May. 27 at 3:41 PM

$ORGO ⏳

1 · Reply

jcooptechit May. 26 at 4:30 PM

0 · Reply

josegodoy May. 22 at 7:07 PM

0 · Reply

Monticello4 May. 22 at 3:52 PM

$ORGO

0 · Reply

josegodoy May. 21 at 7:19 PM

$ORGO &3.75 whenever you’re ready

0 · Reply

josegodoy May. 21 at 3:15 PM

$ORGO 🧐

0 · Reply

Monticello4 May. 19 at 8:31 PM

$ORGO .

0 · Reply

Mobagri May. 15 at 4:29 AM

$ORGO Mimidyx troll Monticello AKA sophisticated investor

0 · Reply

Monticello4 May. 14 at 8:59 PM

$ORGO Here is the real Mobagri, at his finest. Remember that he described himself as a sophisticated investor... sickening. These posts were sent to me and others...we agreed to delete the recipient's names

0 · Reply

Monticello4 May. 14 at 7:50 PM

$ORGO ...😁

0 · Reply

Monticello4 May. 14 at 6:49 PM

$ORGO ===

0 · Reply

Monticello4 May. 14 at 6:48 PM

$ORGO ..

0 · Reply

Monticello4 May. 14 at 6:47 PM

$ORGO ,